. Intramuscular injection of laminin-111 prevents muscle disease in mdx mice. (A) Immunofluorescence of the TA muscles of control and laminin-111-treated mice confirms the absence of dystrophin in mdx muscle treated with LAM-111 or PBS. Laminin-111 was not present in wild-type or PBS-injected mdx muscle, but it was detected in the extracellular matrix of laminin-111-injected mdx muscle. (Scale bar: 10 m.) (B) EBD uptake reveals that mdx muscle injected with laminin-111 exhibits reduced EBD uptake compared with control. (Scale bar: 10 m.) H&E staining reveals that mdx muscle treated with laminin-111 contains few muscle fibers with centrally located nuclei and mononuclear cell infiltrate compared with control. (C) Quantitation reveals wild-type and mdx muscle treated with laminin-111 contained significantly fewer EBD-positive fibers and myofibers with centrally located nuclei compared with control. * , P Ͻ 0.05; ** , P Ͻ 0.001; n ϭ 5 mice per group. Studies suggest laminin may regulate ␣7-integrin expression. To test this hypothesis, mouse and human myoblasts were treated with laminin and assayed for ␣7-integrin expression. We show that laminin-111 (␣1, ␤1, ␥1), which is expressed during embryonic development but absent in normal or dystrophic skeletal muscle, increased ␣7-integrin expression in mouse and DMD patient myoblasts. Injection of laminin-111 protein into the mdx mouse model of DMD increased expression of ␣7-integrin, stabilized the sarcolemma, restored serum creatine kinase to wild-type levels, and protected muscle from exercised-induced damage. These findings demonstrate that laminin-111 is a highly potent therapeutic agent for the mdx mouse model of DMD and represents a paradigm for the systemic delivery of extracellular matrix proteins as therapies for genetic diseases.
␣7␤1-integrin ͉ exercise-induced muscle damage ͉ laminin protein therapy ͉ cell-based screening ͉ LacZ reporter D uchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy, affecting 1 in 3,500 male births. DMD patients suffer from severe, progressive muscle wasting, with clinical symptoms first detected at 2-5 years of age. As the disease progresses, patients are confined to a wheelchair in their teens and die in their early 20s from cardiopulmonary failure. There is currently no effective treatment or cure for DMD.
DMD patients and mdx mice have mutations in the gene encoding dystrophin. These mutations result in the absence of dystrophin, a 427-kDa cytoskeletal protein that, along with the dystrophin-associated proteins, provides a mechanical link between the cell cytoskeleton and laminin in the extracellular matrix (1) (2) (3) (4) (5) . In DMD patients, the compromised dystrophin linkage system causes muscle fibers to detach from the extracellular matrix during muscle contraction, leading to progressive loss of muscle integrity and function (3) .
In the absence of dystrophin, the ␣ 7 ␤ 1 -integrin is up-regulated in the skeletal muscle of DMD patients and mdx mice (6) . The ␣ 7 ␤ 1 -integrin is the predominant laminin-binding integrin in cardiac and skeletal muscle (7) . Mutations in the ␣ 7 -integrin gene cause congenital myopathy in both humans and mice (8) (9) (10) . Transgenic overexpression of the ␣ 7 -integrin in the skeletal muscle of severely dystrophic mice improves muscle pathology and increases lifespan (11) . Conversely, loss of the ␣ 7 -integrin in mdx mice results in a more severe dystrophic phenotype and reduced viability, with mice dying prematurely by 4 weeks of age (12, 13) . Together, these results support the hypothesis that the ␣ 7 ␤ 1 -integrin is a major modifier of muscle disease progression, and drug-based therapies that boost its expression could alleviate DMD.
To identify molecules that promote ␣ 7 -integrin expression, we developed a muscle cell-based assay to report ␣ 7 -integrin promoter activity. Using this assay, we identified that laminin-111 increased ␣ 7 -integrin expression in mouse and DMD muscle cells. Intramuscular or systemic injection of laminin-111 into mdx mice increased ␣ 7 -integrin expression, prevented the onset of muscular dystrophy, and protected muscle from exercise-induced injury. Together, our results identify that laminin-111 is an effective protein therapeutic in the mdx mouse model of DMD.
Results
Laminin-111 Increases ␣7-Integrin Promoter Activity. To test molecules that increase ␣ 7 -integrin expression, we developed a muscle cell-based assay. We have reported previously the production of an ␣ 7 -integrin null mouse in which exon 1 of the ␣ 7 -integrin gene was replaced with the LacZ reporter gene (8) . In these mice, all of the transcriptional regulatory elements of the ␣ 7 -integrin promoter are retained, allowing ␤-galactosidase to report expression from the ␣ 7 -integrin promoter. Primary myoblasts (designated ␣ 7 ␤gal ϩ/Ϫ ) isolated from 10-day-old ␣ 7 ϩ/Ϫ pups were analyzed for the ability of ␤-galactosidase to report ␣ 7 -integrin expression. ␣ 7 ␤gal ϩ/Ϫ myoblasts were differentiated and subjected to X-Gal staining and Western blot analysis ( Fig. 1 A  and B) . ␤-Galactosidase expression in ␣ 7 ␤gal ϩ/Ϫ muscle cells increased upon myogenic differentiation, consistent with the expression pattern of ␣ 7 -integrin in myoblasts and myotubes (14) . These results confirm that the LacZ reporter gene in ␣ 7 ␤gal ϩ/Ϫ muscle cells faithfully reports the transcriptional activity of the ␣ 7 -integrin promoter.
Several lines of evidence suggest positive feedback in the regulation of laminin and ␣ 7 -integrin expression (6, 13, 15) . To test the hypothesis that laminin regulates ␣ 7 -integrin expression, ␣ 7 ␤gal ϩ/Ϫ myoblasts were exposed to 0-200 nM laminin-111 for 24 h. The activity of the ␣ 7 -integrin promoter was measured by ␤-galactosidase cleavage of the nonfluorescent compound fluorescein di-␤-D-galactopyranoside (FDG) to fluorescein. FACS demonstrated that ␣ 7 ␤gal ϩ/Ϫ myoblasts treated for 24 h with 100 nM laminin-111 produced the maximal increase in ␣ 7 -integrin promoter activity (Fig. 1C) . These results indicate laminin-111 promotes expression of ␣ 7 -integrin in isolated mouse muscle cells.
Laminin-111 Enhances ␣7-Integrin Levels in Mouse and Human Muscle
Cells. We next quantified ␣ 7 -integrin levels in C2C12 mouse and DMD primary myoblasts treated with laminin-111. C2C12 myoblasts were treated with 100 nM laminin-111 or PBS for 24 h and analyzed by Western blotting for ␣ 7 B-integrin ( Fig. 2A) . Laminin-111 produced a 2.2-fold increase in ␣ 7 B-integrin in C2C12 myoblasts, confirming that laminin-111 promotes expression of the ␣ 7 ␤ 1 -integrin in mouse myoblasts (Fig. 2B) .
We then determined whether laminin-111 increased ␣ 7 -integrin in DMD muscle cells. Primary DMD myoblasts were treated with 100 nM laminin-111 or PBS for 24 h, and protein extracts were subjected to Western blot analysis for ␣ 7 B-integrin (Fig. 2C ).
Laminin-111 produced a 1.7-fold increase in ␣ 7 B-integrin compared with the PBS-treated cells (Fig. 2D ). These data indicate that the mechanism by which laminin-111 increases ␣ 7 -integrin expression is conserved between mouse and human muscle cells and suggest that laminin-111 is highly likely to increase ␣ 7 -integrin expression in the skeletal muscle of DMD patients.
Intramuscular Injection of Laminin-111 Prevents Muscle Disease in
mdx Mice. We next determined whether laminin-111 increased ␣ 7 -integrin expression in skeletal muscle in vivo. The left tibialis anterior (TA) muscles of 10-day-old mdx mice were injected with 100 L of 100 nM laminin-111, whereas the right TA muscles were injected with 100 L of PBS and served as the contralateral control. At 5 weeks of age, mice were killed, and the TA muscles were harvested. Laminin-111 is not normally expressed in adult or dystrophic muscle, and immunofluorescence revealed the injected laminin-111 protein was deposited throughout the basal lamina of the TA muscle of 5-week-old mdx mice (Fig. 3A) .
To determine whether laminin-111 prevented muscle pathology in mdx mice, Evans blue dye (EBD) uptake and hematoxylin/ eosin (H&E) staining were performed on cryosections from PBS-injected and laminin-111-injected TA muscle (Fig. 3B) . The mdx muscles injected with laminin-111 had 12-fold fewer myofibers positive for EBD compared with the contralateral controls (Fig. 3C ). In addition, mdx muscles injected with laminin-111 showed a 4-fold decrease in the percentage of muscle fibers with centrally located nuclei (Fig. 3C) . These results indicate intramuscular injection of laminin-111 protein dramatically increased sarcolemmal integrity and reduced myofiber degeneration.
Intramuscular Injection of Laminin-111 in mdx Mice Boosts ␣7-Integrin
Expression. To determine the mechanism by which laminin-111 protein therapy protected dystrophin-deficient muscle from damage, immunofluorescence analysis of utrophin and ␣ 7 -integrin was performed. Our results confirm increased expression of both ␣ 7 -integrin and utrophin in mdx skeletal muscle, as reported previously (6, 16) . Laminin-111 treatment further increased expression of ␣ 7 -integrin in the TA muscle of mdx mice (Fig. 4) .
To confirm and quantify these observations, PBS-treated and laminin-111-treated mdx muscles were subjected to Western blot analysis (Fig. 5A) . A 1.6-fold and a 2.6-fold increase in ␣ 7 A-and ␣ 7 B-integrin isoforms, respectively, was observed in laminin-111-treated mdx muscles compared with controls (Fig. 5B) . In addition, a 1.3-fold increase in utrophin was observed in laminin-111-treated muscles (Fig. 5B) . No significant change in ␤ 1 Dintegrin levels was seen, consistent with results reported in ␣ 7 -integrin transgenic mice (11) . These results demonstrate that laminin-111 increased by more than 4-fold the expression of ␣ 7 -integrin, a protein known to alleviate muscle pathology when transgenically overexpressed in dystrophic muscle.
Laminin-111 Protein Can Be Systemically Delivered to mdx Muscle.
DMD patients suffer from generalized muscle wasting, so an effective therapy should target all muscles, including the heart and diaphragm. We therefore determined whether laminin-111 protein could be delivered systemically to these muscles. Ten-day-old mdx pups were injected i.p. with 1 dose of laminin-111 at 1 mg/kg, and tissues were analyzed at 5 weeks of age. Immunofluorescence analysis revealed the presence of laminin-␣1 throughout the basal lamina of gastrocnemius muscle, diaphragm, and cardiomyocytes of laminin-111-injected mice, whereas controls were negative (Fig. 6A and Fig. S1 A) .
We next examined the presence of laminin-111 in other tissues. Laminin-111 is normally expressed in adult kidney (17) , and immunofluorescence detected laminin-␣1 signal in the kidneys of wild-type and PBS-treated mdx mice. The kidneys of laminin-111-treated mdx mice showed increased laminin-␣1 (Fig. 6A) . The brain, liver, and vena cava of wild-type and PBS-treated mdx mice showed no laminin-␣1 signal. In contrast, laminin-111-treated mdx mice showed punctate regions of laminin-␣1 in the liver and strong laminin-␣1 immunofluorescence in the vena cava and blood vessels of the brain (Fig. 6A) . No signal was detected within the brain parenchyma, suggesting laminin-111 protein did not cross the blood-brain barrier. Finally, to confirm systemic delivery, Alexa 488-labeled laminin-111 protein was i.p. injected into mdx mice, and the diaphragm was isolated 48 h later for analysis. Alexa 488-labeled laminin-111 was detected within the diaphragm (Fig. S1B ). These results demonstrate that laminin-111 protein can be systemically delivered to skeletal and cardiac muscles in mdx mice.
To determine whether the injected laminin-111 protein induced expression of endogenous laminin-␣1, RT-PCR was performed (Fig. 6B) . Although laminin-␣1 transcript was detected in mouse kidney, as previously reported (17) , no laminin-␣1 transcript was detected in wild-type or mdx TA muscles treated with PBS or laminin-111 (Fig. 6B) . Quantitative TaqMan RT-PCR confirmed these observations (Fig. 6C) . These data indicate that the injected laminin-111 did not induce expression of endogenous laminin-␣1.
Mdx Mice Treated with Laminin-111 Have Normal Levels of Serum
Creatine Kinase. Serum creatine kinase is highly elevated in DMD patients because of muscle damage. To determine whether systemic delivery of laminin-111 was therapeutic, serum was collected 3 weeks after a single laminin-111 injection, and creatine kinase levels were measured. Laminin-111 therapy resulted in a 2.6-fold reduction in serum creatine kinase levels in mdx mice, which was not statistically different from levels observed in wild-type animals (Fig.  6D ). These results demonstrate that a single systemic dose of laminin-111 prevents dystrophic pathology in mdx mice.
Because laminin-111 is a large protein and could potentially adversely affect renal function, we measured serum creatinine and blood urea nitrogen (BUN). Creatinine and BUN were not statistically different between laminin-111-treated mdx and con- trol mice (Fig. 6 E and F) . These data indicate laminin-111 protein therapy had no adverse effects on renal function. To examine whether laminin-111 protein therapy could prevent exercise-induced muscle damage, mdx mice treated with PBS or laminin-111 were subjected to downhill treadmill running, and sarcolemmal integrity was analyzed by EBD uptake. Although the TA muscles of PBS-treated mdx mice showed large numbers of EBD-positive myofibers, mice treated with laminin-111 showed few positive muscle fibers (Fig. 7A) .
Quantitation of these observations revealed that downhill treadmill running produced a 32-fold increase in EBD-positive myofibers compared with nonexercised mice (Fig. 7B) . Thus, downhill running induced significant muscle damage in mdx mice. In contrast, exercised laminin-111-treated mdx mice showed 28-fold fewer EBD-positive muscle fibers compared with PBS-treated exercised mice. These data indicate that laminin-111 protein therapy protected dystrophin-deficient muscle from exercise-induced damage.
Discussion
Despite years of intense research, there is still no effective treatment or cure for DMD. Several genes have been shown to compensate for the loss of dystrophin and rescue dystrophic mice, including ␣ 7 ␤ 1 -integrin (11, 18) . Studies demonstrate that ␣ 7 ␤ 1 -integrin contributes to the structural and functional integrity of skeletal muscle (18) (19) (20) . Because ␣ 7 ␤ 1 -integrin is expressed ubiquitously in skeletal and cardiac muscles, small molecule-based or protein-based approaches that target the expression of this gene hold significant promise for the treatment of DMD.
In this study, we have identified laminin-111 as a protein therapeutic for the mdx mouse model of DMD. Although laminin-111 is not expressed in normal or dystrophic adult skeletal muscle, studies indicate it is a preferred ligand for ␣ 7 ␤ 1 -integrin (21, 22) . Treatment with laminin-111 stabilized the sarcolemma of mdx skeletal muscle, reduced myofiber degeneration, decreased serum creatine kinase, and protected muscle from exercise-induced injury, suggesting that treatment with laminin-111 may be a potent therapy for DMD.
DMD patients typically succumb to cardiopulmonary failure, and systemically delivered therapies should distribute to both skeletal and cardiac muscles. To our surprise, i.p. injected laminin-111 distributed throughout the basal lamina of limb, diaphragm, and cardiac muscles. Laminin-111 was therapeutic, with treated mdx mice showing wild-type levels of serum creatine kinase. The relatively large molecular mass of laminin-111 protein (900 kDa) does not appear to be a barrier to distribution to muscle, and studies have demonstrated that molecules as large as IgM (Ϸ900 kDa) enter the endomysial and perimysial spaces of normal human, DMD, and mdx muscles (23) .
The muscles of DMD patients and mdx mice are highly susceptible to contraction-induced injury, and exercise induces significant sarcolemmal damage in mdx mice (24, 25) . In this study, we show that systemic delivery of laminin-111 not only prevents dystrophindeficient muscle from degeneration but also protects muscle from contraction-induced injury. These results strongly suggest that laminin protein therapy may prevent the repetitive cycles of injury, fibrosis, and loss of muscle function in DMD.
The mechanism underlying the protection by laminin-111 in mdx muscle may involve elevated levels of compensatory proteins and/or improved adhesion. Our studies demonstrate a Ϸ4-fold increase in ␣ 7 -integrin, which has been shown to be therapeutic in dystrophic mice (11, 18) . The small increase in utrophin observed with laminin-111 treatment is unlikely to account for the improvement in muscle pathology because studies suggest significantly more utrophin is required to be therapeutic (26) . In addition to elevated levels of ␣ 7 -integrin, laminin-111 may also act mechanistically to reinforce the sarcolemma against the shear forces experienced during muscle contraction.
Our study demonstrates that laminin-111 may be a highly potent protein therapeutic for DMD. In addition, laminin-111 protein therapy may prove effective in the treatment of other muscle diseases, including congenital muscular dystrophy type 1A, limbgirdle muscular dystrophy, and ␣ 7 -integrin congenital myopathy. The effectiveness of laminin-111 in the DMD mouse model suggests that systemic delivery of extracellular matrix molecules represents a novel paradigm for the treatment of many genetic diseases.
Materials and Methods
Mice. C57BL/10ScSn (wild-type) and C57BL/10ScSn-Dmdmdx/J (mdx) strains of mice (Jackson Laboratories) were used in these studies in accordance with an Quantitation reveals laminin-111-treated mdx muscle has a 1.6-fold and a 2.6-fold increase in ␣7A-and ␣7B-integrin, respectively, compared with control. A 1.3-fold increase in utrophin levels was observed in mdx muscle injected with laminin-111 compared with control. Protein loading was normalized to Cox-1. * , P Ͻ 0.05; ** , P Ͻ 0.001; n ϭ 5 mice per group. animal protocol approved by the University of Nevada, Reno, Institutional Animal Care and Use Committee.
Isolation of ␣7␤gal ؉/؊ Myoblasts. The gastrocnemius muscles were removed from 10-day-old ␣7␤gal ϩ/Ϫ mice, and cells were enzymatically dissociated with 1.25 mg/mL collagenase type II (Worthington Biochemical) for 1 h at 37°C. Myoblasts were separated from muscle fiber fragments and maintained in DMEM supplemented with 10% FBS, 0.5% chicken embryo extract, 1% L-glutamine, and 1% penicillin/streptomycin. ␤-Galactosidase Staining. Cells were fixed in 4% paraformaldehyde and permeabilized with a sodium deoxycholate/Nonidet P-40 mixture for 30 min. X-Gal staining solution (50 mM potassium ferrocyanide, 50 mM potassium ferricyanide, 1 mM MgCl 2, and 100 mg/mL X-Gal) was added to the plates and incubated at 37°C for 2 h. Images were captured with a Nikon Eclipse T5100 microscope and Nikon Coolpix 5400 digital camera.
Laminin-111 Protein Treatment. Natural mouse laminin-111 (␣ 1, ␤1, ␥1) protein (Invitrogen) purified from Engelbreth-Holm-Swarm mouse sarcoma cells at 100 nM in PBS was injected into the left TA muscles of 10-day-old mdx mice. The contralateral right TA muscles were injected with PBS and served as a control. Mice were killed, and muscles were harvested at 5 weeks of age. For systemic delivery, 1 mg/kg laminin-111 protein in PBS was injected i.p. at 10 days, and tissues were harvested for analysis at 5 weeks of age. Control mdx mice were injected with the same volume of PBS.
An Alexa Fluor 488 Protein Labeling Kit (Invitrogen) was used to directly label laminin-111, following the manufacturer's instructions. Alexa 488-labeled laminin-111 was administered i.p. into 10-day-old mdx mice, mice were killed 48 h later, and tissues were collected for analysis. Tissues were fixed with 4% paraformaldehyde, and images were captured at 1,000ϫ magnification. EBD Uptake. Mice were injected i.p. with sterile EBD solution as described previously (13) . Muscle fibers were delineated by using Oregon Green-488-conjugated wheat germ agglutinin (Invitrogen). A minimum of 1,000 fibers per animal were counted to determine the percentage of muscle fibers positive for EBD uptake. At least 5 animals from each genotype were analyzed. Images were captured and counted at 630ϫ magnification.
Exercise-Induced Muscle Injury. At 10 days of age, mdx mice were injected i.p. with 1 mg/kg laminin-111 or PBS. At 5 weeks of age, mice were placed on a Simplex II treadmill (Columbus Instruments) and completed a single downhill running exercise protocol using a modification of previously reported procedures (Ϫ12°, 15 m/min, 25-30 min) (19) . The speed was gradually increased from 10 to 15 m/min during a 2-min warm-up period. Mice were then injected with EBD, and tissues were harvested 24 h later.
Blood Chemistry. Sera were collected and sent to the Comparative Pathology Laboratory at the University of California, Davis, to assay for creatine kinase, creatine, and BUN. Immunofluorescence. Tissues were prepared as described previously (13) . Laminin-␣1 was detected with a 1:500 dilution of the rat monoclonal antibody MAB1903 (Chemicon International) followed by a 1:1,000 dilution of FITCconjugated anti-rat secondary antibody. The ␣7-integrin, ␤1D-integrin, and dystrophin were detected as described previously (8) . Fluorescence was observed with a Zeiss Axioskop 2 Plus fluorescent microscope, and images were captured with Zeiss AxioCam HRc digital camera and Axiovision 4.1 software.
Histology. Tissue sections were stained with H&E as described previously (13) . The percentage of muscle fibers containing centrally located nuclei was determined by counting a minimum of 1,000 muscle fibers per animal. At least 5 animals from each genotype were analyzed.
Immunoblotting. The ␣7-integrin, dystrophin, and utrophin were detected and normalized to Cox-1 as described previously (13) . ␤-Galactosidase was detected by using an anti-␤-galactosidase mouse monoclonal antibody (Promega) at 1:2,000, and equal protein loading was determined by using anti-␣-tubulin (Abcam). Band intensities were quantified by using ImageQuant TL software (Amersham Biosciences).
RNA Isolation, RT-PCR, and Quantitative RT-PCR. RNA was isolated from kidney and TA muscles as described previously (8) . Laminin-␣1 transcript was detected with the following primers: forward, 5Ј-TGTAGATGGCAAGGTCTTATTTCA-3Ј; reverse, 5Ј-CTCAGGCAGTTCTGTTTGATGT-3Ј. The QuantumRNA Classic 18S internal standard (Applied Biosystems/Ambion) was used as a control. Multiplex PCRs were performed by using 100 ng of cDNA. PCR products were separated on 3% agarose gels.
Quantitative real-time TaqMan PCR was performed by using a 7900HT Fast Real-Time PCR System with Fast 96-Well Block Module (Applied Biosystems). Quantitation of 18S rRNA served as a control. All samples were amplified in triplicate, and analysis was performed by using 7500 Fast System Software (Applied Biosystems).
Statistical Analysis. All averaged data are reported as the mean Ϯ standard deviation. Comparisons between multiple groups were performed by 1-way ANOVA for parametric data or by Kruskal-Wallis 1-way ANOVA on ranks for nonparametric data using SigmaStat 1.0 software (Jandel). P Ͻ 0.05 was considered statistically significant. 
